#2026-05322Metastazın Önlenmesi Amaçlı Kan Işınlama Cihazları İçin Ön Pazar Onay Başvurularının Etki Tarihi
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is proposing to require premarket approval (the strictest regulatory pathway) for blood irradiation devices used during cancer surgery to prevent tumor spread. Currently these devices are unclassified and don't need FDA approval. This affects medical device manufacturers, hospitals performing cancer surgeries, and cancer patients. More regulatory scrutiny could improve safety but may also increase costs and limit availability of these specialized devices.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Action
Proposed amendment; proposed order.
Obligations
What this law requires
Blood irradiator manufacturers must file a premarket approval (PMA) application with the FDA before marketing devices intended to irradiate intraoperatively salvaged blood for cancer patients to prevent metastasis
Blood irradiator devices must meet all PMA requirements under the Federal Food, Drug, and Cosmetic Act before commercial distribution
Manufacturers must provide FDA with findings and data regarding the degree of risk of illness or injury that the device is designed to eliminate or reduce
Manufacturers must submit information demonstrating the benefits to the public from use of blood irradiator devices as part of the PMA application